What Is Considered a High CA 27-29 Level?

A CA 27-29 level above roughly 38 to 40 units per milliliter (U/mL) is generally considered elevated, though the exact cutoff depends on which laboratory performs the test and the reference population it uses. In healthy women without disease, measured levels tend to cluster well below that threshold, with one study of 112 disease-free women finding a mean of about 12 U/mL. The number itself, however, tells only part of the story: a single elevated reading does not automatically signal cancer, and a normal reading does not rule it out. What matters clinically is why the test was ordered, how the result fits with the rest of the picture, and whether the value is trending upward over time.

How the Normal Range Is Determined

Labs establish a “normal” cutoff by measuring CA 27-29 in a group of people known to be free of malignant disease, calculating the mean and the statistical spread, and drawing a line a few standard deviations above that mean. One widely cited study set the upper limit of normal at 25 U/mL based on a mean of 12.4 U/mL in 112 healthy female subjects.¹ Other laboratories use a cutoff closer to 38 or 40 U/mL. The American Cancer Society has stated that a normal CA 27-29 level is usually less than 40 U/mL, with the caveat that the number varies by testing facility. This discrepancy is not an error; it reflects different reference populations, different assay kits, and different statistical thresholds chosen by each lab. When you receive a result, the reference range printed on your report is the one that applies to you.

Because of this lab-to-lab variation, comparing a CA 27-29 value drawn at one institution with a value drawn at another can be misleading. If your oncologist is tracking this marker over time, consistency matters: same lab, same assay, same conditions. A jump from 30 to 50 U/mL at the same lab is meaningful. A jump from 30 at one facility to 50 at another might just be a difference in how the two labs calibrate the test.

What CA 27-29 Actually Measures

CA 27-29 is a fragment of a protein called MUC1, a large glycoprotein that sits on the surface of many types of epithelial cells. Most carcinoma cells express MUC1, and bits of it get shed into the bloodstream, where the CA 27-29 assay detects them.² The test is used almost exclusively in the context of breast cancer, though MUC1 is not unique to breast tissue. Cancers of the colon, lung, ovary, and other organs can also shed MUC1, and some benign conditions raise it too. This is one of the reasons the test is not used as a screening tool for the general population: it simply is not specific enough to say with confidence that an elevated reading means cancer.

You will sometimes see CA 27-29 mentioned alongside CA 15-3. Both measure MUC1, but they target slightly different epitopes on the same protein. In practice, they perform similarly. One head-to-head study found that in breast cancer patients, CA 27-29 ran slightly higher than CA 15-3, while in healthy subjects the reverse was true. The area under the curve for CA 27-29 was larger, suggesting modestly better diagnostic accuracy in that particular study population.³ Neither test has a clear across-the-board advantage, and many oncologists treat them as interchangeable when monitoring the same patient.

Where This Marker Is Most Useful

CA 27-29 performs best in the setting it was designed for: tracking metastatic breast cancer. In patients with known metastatic disease, sensitivity is high. One study reported CA 27-29 sensitivity of about 86% in patients with metastases, with the highest values seen in those with liver and bone involvement.¹ Another study of metastatic patients found CA 27-29 sensitivity around 70%, with liver and bone sites again producing the highest readings.⁴ The difference between those two numbers reflects different study populations, different cutoffs, and different mixtures of metastatic sites, but the overall picture is consistent: when breast cancer has spread, CA 27-29 is quite likely to be elevated, and the further the disease has progressed, the higher it tends to go. Mean values in metastatic patients reached about 153 U/mL in one cohort, compared with about 10 U/mL in patients without metastases.¹

The marker is also useful for gauging whether treatment is working. In patients receiving therapy for metastatic disease, CA 27-29 correlated with the clinical course of illness about 81% of the time, a match rate similar to CA 15-3.⁴ If a patient starts a new chemotherapy regimen and CA 27-29 falls steadily, that is a good sign. If it climbs during treatment, it suggests the cancer may not be responding.

Why a Single High Reading in Early-Stage Disease Means Less

The picture changes sharply when you look at early-stage breast cancer patients without distant spread. In that group, CA 27-29 sensitivity drops to single digits. One study found sensitivity of just 6.4% in non-metastatic breast cancer patients.¹ In other words, the vast majority of early-stage patients had normal CA 27-29 levels. This means the test cannot tell you whether early-stage cancer is present, and a normal result offers almost no reassurance that cancer has not returned after surgery.

A large analysis of high-risk early breast cancer patients found a more nuanced relationship. CA 27-29 measured before chemotherapy was associated with disease-free survival overall, but only in certain subgroups. In patients whose tumors had not spread to the lymph nodes, there was no meaningful association between the pre-treatment marker level and later outcomes. In node-positive patients with very small tumors, only a minor association appeared. And CA 27-29 measured after chemotherapy showed no predictive value at all.⁵ The takeaway for patients: a mildly elevated CA 27-29 in the early-stage setting does not reliably predict what will happen next.

How Breast Cancer Subtype Affects the Result

Not all breast cancers shed MUC1 at the same rate. Luminal subtypes, which express hormone receptors, are the most likely to produce elevated tumor markers. In a study of metastatic breast cancer, roughly 89% to 91% of luminal cases had at least one elevated tumor marker, compared with about a quarter of triple-negative cases showing no marker elevation at all.⁶ CA 15-3, a close relative of CA 27-29, was elevated in over 80% of luminal cases but only about 69% of triple-negative cases.

This has practical consequences. If you have a triple-negative breast cancer and your CA 27-29 is normal, that does not necessarily mean you are in the clear. The biology of your tumor type means it is simply less likely to push the marker above the threshold. Conversely, a high reading in a luminal cancer is somewhat expected and should be interpreted alongside imaging and clinical exam rather than treated as alarming on its own.

Non-Cancer Reasons for an Elevated Reading

Because MUC1 is expressed on normal epithelial cells throughout the body, not only on cancer cells, several benign conditions can push CA 27-29 above the reference range. Liver disease, kidney dysfunction, and some inflammatory conditions affecting the lungs or the lining of the abdomen have been associated with mildly elevated MUC1-based markers. Ovarian cysts, endometriosis, and benign breast disease can also cause modest bumps. Even pregnancy is known to raise MUC1 levels.

The practical implication is straightforward: if your doctor orders a CA 27-29 outside the context of known breast cancer and it comes back slightly elevated, the first step is not panic but investigation. A reading of 45 or 50 U/mL in someone with chronic liver disease or an active inflammatory condition does not carry the same weight as the same reading in a breast cancer patient whose previous values have been normal. Context determines meaning.

When Treatment Itself Raises the Number

Certain cancer treatments can temporarily inflate CA 27-29 levels, creating a confusing picture. One particularly well-documented culprit is G-CSF, a growth factor commonly given to boost white blood cell counts during or after chemotherapy. A large trial found that G-CSF treatment was associated with increased CA 27-29 levels after chemotherapy, meaning that a post-treatment spike in the marker might reflect the supportive medication rather than disease progression.⁷ The authors cautioned that elevated CA 27-29 readings shortly after adjuvant chemotherapy with G-CSF should be interpreted with care.

A phenomenon known as a “tumor marker flare” can also occur in the first weeks after starting a new treatment. The marker spikes temporarily as tumor cells break apart and release MUC1 into the blood, then falls as the treatment takes effect. If a clinician checks the marker too soon after a therapy change and sees a high reading, it can trigger unnecessary imaging or even a premature switch to a different regimen. Most oncologists familiar with this pattern will wait several weeks before drawing conclusions from a post-treatment result.

The Guideline Debate

Professional guidelines on CA 27-29 are not unanimous, and the tension reflects a genuine disagreement in the oncology community. The American Society of Clinical Oncology (ASCO) does not recommend using CA 15-3 or CA 27-29 for routine surveillance after primary breast cancer therapy. The concern is that detecting a rise in the marker before symptoms appear has not been convincingly shown to improve survival, and it can drive additional testing, cost, and anxiety without clear benefit.⁸

On the other hand, several studies have demonstrated that a rising CA 27-29 can predict recurrence an average of five to six months before clinical symptoms or imaging findings reveal it.⁸ Similarly, CA 15-3 and CA 27-29 values were found to increase on average three months before clinical diagnosis in another study of metastatic patients.⁴ The unresolved question is whether that early warning translates into better outcomes. Catching a recurrence a few months earlier only helps if there is an effective intervention available that works better when started sooner. For some patients and some treatment scenarios, that lead time may matter. For others, it may just mean knowing bad news earlier without changing anything actionable.

In practice, many oncologists order the test anyway, especially for patients with metastatic disease or those considered high risk, even if the guidelines are lukewarm. The test is inexpensive, requires only a blood draw, and provides a data point that, when combined with imaging and clinical assessment, can help guide treatment decisions. It just should not be the sole basis for those decisions.

Why Trends Matter More Than Any Single Number

If there is one principle that ties all of this together, it is that a single CA 27-29 value, high or low, is far less informative than a series of values tracked over time. A reading of 42 U/mL in isolation could be a benign fluctuation, a lab variation, or the first sign of something serious. That same reading plotted against the previous four readings tells a story: has the value been climbing steadily from 20, to 30, to 42? Or did it jump from 38 to 42 and plateau? The trajectory, not the snapshot, is what drives clinical decision-making.

Oncologists typically look for a sustained upward trend, often confirmed by a repeat draw a few weeks later, before acting on an elevated result. A single reading that crosses the cutoff is rarely treated as an emergency. A confirmed, progressive rise usually triggers imaging to look for recurrence or metastatic disease. And a falling trend during treatment is one of the clearest signals that the therapy is working, especially in the metastatic setting where the marker correlates well with the course of illness.

The Cost Side of Routine Marker Testing

For patients who are tracked with tumor markers, the financial ripple effects extend beyond the cost of the blood test itself. An elevated or ambiguous result often leads to additional imaging, biopsies, and specialist consultations. A study of older early-stage breast cancer survivors found that medical costs for patients who received at least one tumor marker test were roughly 29% higher than costs for those who did not, after adjusting for other factors.⁹ That does not necessarily mean the testing caused all of that extra spending; patients who get tested may also be sicker or more closely followed for other reasons. But the association highlights a real concern: routine marker surveillance in early-stage patients, where sensitivity is low and false positives are relatively common, can generate a cascade of downstream costs and procedures that may not improve outcomes.

This is worth keeping in mind if your oncologist checks CA 27-29 at every follow-up visit. The test itself is cheap. The workup triggered by a mildly elevated result is not. If you are an early-stage patient with no symptoms and your only concerning finding is a CA 27-29 of 41, it is entirely reasonable to ask your doctor whether a repeat draw in a few weeks makes more sense than jumping straight to a CT scan.

Combining Markers for Better Accuracy

No single tumor marker captures the full picture in breast cancer. This is why oncologists sometimes order CA 27-29 alongside other markers like CEA, a more general cancer antigen. Each marker has strengths in different settings. CEA, for example, is less sensitive overall than CA 27-29 in metastatic disease, with one study reporting sensitivity around 63% for CEA compared with about 86% for CA 27-29 in patients with metastases.¹ But in locoregional relapses, where cancer recurs near the original tumor site rather than in distant organs, adding CEA to the panel improved detection from about 40% to 60%.⁴ Similarly, combining CA 15-3 and CA 27-29 pushed sensitivity for bone metastases from 80% to 85%.⁴

These incremental gains may sound modest, but in clinical practice, catching even one additional recurrence early can be significant for an individual patient. The tradeoff is complexity and cost: more markers mean more blood draws, more results to interpret, and more chances for a false positive to set off a chain of unnecessary follow-up. Most oncologists tailor the panel to the patient’s specific risk profile and the sites most likely to be involved if recurrence occurs.

Emerging Approaches to Monitoring

Tumor marker monitoring is an area of active research. Newer approaches like circulating tumor DNA (ctDNA) testing can detect fragments of cancer-specific genetic material in the blood with potentially greater specificity than protein-based markers like CA 27-29. Early studies suggest ctDNA can identify molecular recurrence months before it becomes visible on scans, without the same false-positive issues that plague MUC1-based assays. Whether ctDNA monitoring will eventually replace CA 27-29 in routine practice remains to be seen, but it represents a fundamentally different approach: instead of measuring a protein that normal cells also produce, it looks for DNA mutations that only the tumor carries.

For now, CA 27-29 remains a standard part of the breast cancer monitoring toolkit, especially in the metastatic setting. Its limitations are real and well documented, but so are its strengths. A patient with metastatic breast cancer whose CA 27-29 drops from 200 to 40 over three months of treatment has a concrete, quantifiable signal that things are heading in the right direction. That kind of reassurance, drawn from a simple blood test, still has considerable value even as the field moves toward more sophisticated technologies.